AU2022213409A1 - Detecting the presence or absence of multiple types of cancer - Google Patents

Detecting the presence or absence of multiple types of cancer Download PDF

Info

Publication number
AU2022213409A1
AU2022213409A1 AU2022213409A AU2022213409A AU2022213409A1 AU 2022213409 A1 AU2022213409 A1 AU 2022213409A1 AU 2022213409 A AU2022213409 A AU 2022213409A AU 2022213409 A AU2022213409 A AU 2022213409A AU 2022213409 A1 AU2022213409 A1 AU 2022213409A1
Authority
AU
Australia
Prior art keywords
cancer
methylation
sample
markers
methylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022213409A
Other languages
English (en)
Other versions
AU2022213409A9 (en
Inventor
AHLQUIST (DECEASED), David A.
Hatim T. Allawi
Viatcheslav E. KATEROV
John B. Kisiel
Douglas W. Mahoney
William R. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exact Sciences Corp
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Exact Sciences Corp
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Exact Sciences Corp, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2022213409A1 publication Critical patent/AU2022213409A1/en
Publication of AU2022213409A9 publication Critical patent/AU2022213409A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00—Reactions characterised by treatment of reaction samples
    • C12Q2523/10—Characterised by chemical treatment
    • C12Q2523/125—Bisulfite(s)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2022213409A 2021-01-29 2022-01-28 Detecting the presence or absence of multiple types of cancer Pending AU2022213409A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163143611P 2021-01-29 2021-01-29
US63/143,611 2021-01-29
US202163278889P 2021-11-12 2021-11-12
US63/278,889 2021-11-12
PCT/US2022/014408 WO2022165247A1 (en) 2021-01-29 2022-01-28 Detecting the presence or absence of multiple types of cancer

Publications (2)

Publication Number Publication Date
AU2022213409A1 true AU2022213409A1 (en) 2023-08-17
AU2022213409A9 AU2022213409A9 (en) 2024-10-17

Family

ID=82613439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022213409A Pending AU2022213409A1 (en) 2021-01-29 2022-01-28 Detecting the presence or absence of multiple types of cancer

Country Status (7)

Country Link
US (1) US20220243278A1 (https=)
EP (1) EP4284951A4 (https=)
JP (1) JP2024506854A (https=)
KR (1) KR20230150814A (https=)
AU (1) AU2022213409A1 (https=)
CA (1) CA3206781A1 (https=)
WO (1) WO2022165247A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2816122A1 (en) 2008-02-15 2014-12-24 Mayo Foundation For Medical Education And Research Detecting neoplasm from a stool sample
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
EP4234722A3 (en) 2014-03-31 2023-09-20 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
CN108138235B (zh) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
AU2016343937B2 (en) 2015-10-30 2023-01-19 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of DNA from plasma
KR102892245B1 (ko) 2017-01-27 2025-11-27 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 메틸화된 dna 분석에 의한 결장 신조직형성의 검출
US10975443B2 (en) 2017-11-30 2021-04-13 Mayo Foundation For Medical Education And Research Detecting breast cancer
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US12584177B2 (en) 2019-01-24 2026-03-24 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
CA3154354A1 (en) 2019-10-31 2021-05-06 William R. Taylor Detecting ovarian cancer
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
CN115725734B (zh) * 2022-08-10 2023-10-13 人和未来生物科技（长沙）有限公司 Znf781基因在制备宫颈癌诊断试剂中的应用
JP2025539812A (ja) * 2022-11-17 2025-12-09 メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ 泌尿器癌を検出するための組成物及び方法
CN116144773A (zh) * 2022-11-30 2023-05-23 广州康立明生物科技股份有限公司 一种宫颈病变分子诊断试剂
CN116200499B (zh) * 2023-03-23 2024-01-19 北京和瑞精湛医学检验实验室有限公司 一种用于肝癌检测的基因组合与相关试剂和应用
WO2024222519A1 (zh) * 2023-04-26 2024-10-31 博尔诚（北京）科技有限公司 用于检测肝癌的组合物及其用途
WO2025032045A1 (en) * 2023-08-04 2025-02-13 Universiteit Antwerpen Multi-cancer detection assay
CN117310178A (zh) * 2023-09-13 2023-12-29 南通大学 一种用于诊断肝癌预后的生物标志物及其siRNA靶向药物的应用
KR20250081367A (ko) * 2023-11-29 2025-06-05 주식회사 지씨지놈 식도암 및 위암 방사선 치료 반응성 예측용 dna 메틸화 마커 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501439C2 (sv) 1993-06-22 1995-02-13 Pharmacia Lkb Biotech Sätt och anordning för analys av polynukleotidsekvenser
AU1061395A (en) 1993-11-30 1995-06-19 Mcgill University Inhibition of dna methyltransferase
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6251594B1 (en) 1997-06-09 2001-06-26 Usc/Norris Comprehensive Cancer Ctr. Cancer diagnostic method based upon DNA methylation differences
DE19754482A1 (de) 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
US7700324B1 (en) 1998-11-03 2010-04-20 The Johns Hopkins University School Of Medicine Methylated CpG island amplification (MCA)
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
EP3048176B1 (en) * 2009-04-20 2019-03-06 Erasmus University Medical Center Rotterdam Method of diagnosing bladder cancer
WO2011127136A1 (en) 2010-04-06 2011-10-13 University Of Chicago Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmc)
US8715937B2 (en) 2010-11-15 2014-05-06 Exact Sciences Corporation Mutation detection assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8808990B2 (en) 2011-05-12 2014-08-19 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
CN103649298A (zh) 2011-05-12 2014-03-19 精密科学公司 核酸的分离
CA2863215C (en) 2012-01-30 2021-05-04 Exact Sciences Corporation Modification of dna on magnetic beads
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
WO2015066695A1 (en) 2013-11-04 2015-05-07 Exact Sciences Corporation Multiple-control calibrators for dna quantitation
CN108138235B (zh) * 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
AU2016343937B2 (en) 2015-10-30 2023-01-19 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of DNA from plasma
US11162139B2 (en) 2016-03-02 2021-11-02 Shanghai Epican Genetech Co. Ltd. Method for genomic profiling of DNA 5-methylcytosine and 5-hydroxymethylcytosine
MX391039B (es) 2016-04-07 2025-03-21 Univ Leland Stanford Junior Diagnostico no invasivo por medio de la secuenciacion del adn libre de celulas 5-hidroxi-metilado.
CN116064796A (zh) * 2016-05-05 2023-05-05 精密科学公司 通过分析甲基化dna来检测肺肿瘤
PL3336197T3 (pl) * 2016-12-16 2022-08-08 Eurofins Genomics Europe Sequencing GmbH Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika
JP7136899B2 (ja) 2018-01-08 2022-09-13 ルドウイグ インスティテュート フォー キャンサー リサーチ エルティーディー シトシン修飾の、亜硫酸水素塩非含有、塩基分解能特定
CN119753091A (zh) * 2018-04-02 2025-04-04 格里尔公司 用于扩增与癌症相关联的cfDNA分子的化验板
BR112021009795A2 (pt) * 2018-11-27 2021-08-17 Exact Sciences Development Company, Llc métodos de caracterização e para caracterizar uma amostra, kit e composição
US12584177B2 (en) * 2019-01-24 2026-03-24 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
EP3948292A4 (en) * 2019-04-03 2023-01-18 Mayo Foundation for Medical Education and Research DETECTION OF DUCTAL PANCREATIC CARCINOMA IN PLASMA
GB201908624D0 (en) * 2019-06-17 2019-07-31 Vib Vzw Predicting age using dna methylation signatures

Also Published As

Publication number Publication date
CA3206781A1 (en) 2022-08-04
JP2024506854A (ja) 2024-02-15
US20220243278A1 (en) 2022-08-04
KR20230150814A (ko) 2023-10-31
WO2022165247A1 (en) 2022-08-04
AU2022213409A9 (en) 2024-10-17
EP4284951A1 (en) 2023-12-06
EP4284951A4 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
US20220243278A1 (en) Detecting the presence or absence of multiple types of cancer
US20260071277A1 (en) Compositions and methods for detecting oropharyngeal cancer
USRE50621E1 (en) Detecting breast cancer
US20220349009A1 (en) Detecting esophageal disorders
US20230357852A1 (en) Detecting non-hodgkin lymphoma
KR20230154433A (ko) 자궁경부암의 검출
EP4146678A2 (en) Detecting pancreatic neuroendocrine tumors
CN117043358A (zh) 检测多种类型的癌症的存在或不存在
WO2021226074A2 (en) Detecting melanoma
US20240110245A1 (en) Compositions and methods for detecting gynecological cancer
WO2024108111A1 (en) Compositions and methods for detecting urological cancer
EP4638801A1 (en) Compositions and methods for detecting esophageal cancer

Legal Events

Date Code Title Description
SREP Specification republished